STING agonist-22

STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research. In Vitro STING agonist-22 (CF501) leads to rapid and robust activation of innate immune responses in THP-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo STING agonist-22 (CF501) robustly, but transiently, activates innate immunity with acceptable safety profile in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c mice (female, six weeks old) Dosage: 20, 75 μg Administration: Intramuscular injection Result: Although innate immunity was activated only transiently by CF501, it should be sufficient to stimulate the required humoral and cellular immune responses. The half-life of CF501 was 0.5 h and there was no detectable CF501 in the plasma after 2 h of the injection. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet